Decoy receptor 3 (DcR3) as a biomarker of tumor deterioration in female reproductive cancers: A meta-analysis

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 1850-1857

  Jiang, Mengtong ^a   Lin, Xiaomiao ^b   He, Rongquan ^a   Lin, Xinggu ^a   Liang, Lu ^a   Tang, Ruixue ^a   Xiong, Dandan ^a   Wei, Kanglai ^a   Dang, Yiwu ^a   Feng, Zhenbo ^a   Chen, Gang ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b Guangxi Maternal and Child Health Hospital   (China)

Author keywords

Genes, neoplasm; Genital diseases, female; Meta Analysis; Prognosis; Receptors, tumor necrosis factor, member 6b; Survival analysis

Indexed keywords

DECOY RECEPTOR 3; TNFRSF6B PROTEIN, HUMAN; TUMOR MARKER;

AGE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; DETERIORATION; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; LYMPH NODE METASTASIS; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR DETERIORATION; TUMOR DIFFERENTIATION; UTERINE CERVIX CANCER; BIOSYNTHESIS; BREAST TUMOR; CASE CONTROL STUDY; FEMALE GENITAL TRACT TUMOR; GENETICS; META ANALYSIS; METABOLISM; ODDS RATIO; OVARY TUMOR; PATHOLOGY; PROGNOSIS; UTERINE CERVIX TUMOR;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LYMPHATIC METASTASIS; ODDS RATIO; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; UTERINE CERVICAL NEOPLASMS;

EID: 84977556895     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.896226     Document Type: Article

References (43)

1. Takahama Y, Yamada Y, Emoto K et al: The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer, 2002; 5: 61–68
2. Chen G, Luo DZ, Wang Y et al: Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi, 2007; 36: 113–17
3. Wu Y, Han B, Sheng H et al: Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer, 2003; 105: 724–32
4. Pitti RM, Marsters SA, Lawrence DA et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 1998; 396: 699–703
5. Gao SS: Expression of DcR3 and micro vessel density marked with CDl05 in cervical carcinoma and its significance. China Modern Doctor, 2013; 26: 32–34+161
6. Cheng L, Yang YH, Zhou CR et al: Expression of decoy receptor 3 in epithelia ovarian carcinoma and its clinical significance. J Mod Oncol, 2015; 1: 116–19
7. Wang LP, Chen J, Ning HY et al: Function, expression and significance of TR6 in breast cancer. Chinese J Diagn Pathol, 2005; 2: 57–60+97
8. Tong J, Ao R, Wang Y et al: Prognostic and clinicopathological of DcR3 in gastrointestinal cancer: evidence from meta-analysis. Int J Clin Exp Med, 2014; 7: 3096–105
9. Ayed ME, Bonnel D, Longuespee R et al: MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit, 2010; 16(8): BR233–45
10. Balakan O, Kalender ME, Suner A et al: The relationship between Urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med Sci Monit, 2014; 20: 1419–25
11. Pan DH, Wei KL, Ling YX et al: The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis. Med Sci Monit, 2015; 21: 882–89
12. Lu JH, Xiong M, Shu HM et al: Expression and clinical significance of DcR3 in cervical intraepithelial neoplasia and cervical cancer. Chin J Obstet Cynecol, 2012; 47: 150–52
13. Cao YX: DcR3 expression and clinical significance of research in cervical cancer. Central South University, 2011
14. Wang ZR, Xing LY, Liu NX et al: Expression and clinical significance of DcR3 in cervical cancer. J Xi’an Jiaotong University (Medical Sciences), 2013; 2: 224–28
15. Joseph P, Connor JP, Felder M: Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol, 2008; 111: 300–5
16. Wang JO, Lv QJ, Jiang WG et al: Expression of DcR3 in ovarian cancer and its significance. J Oncol, 2009; 11: 988–89
17. Gao HH: The investigation about the correlation of DcR3 with lymphangiogenesis and lymphatic Metastasis in breast cancer. Fujian Medical University, 2011
18. Shan GP, Xu MR, Lv QS, Chi MM: Expression of DcR3 in breast cancer and its clinical significance. Chin J Clin Oncol Rehabil, 2007; 2: 97–100
19. Chen G, Dang YW, Yang MSZ, Luo DZ: Tumor necrosis factor receptor 6 expression and clinical significance in breast cancer. J Practical Med, 2010; 19: 3539–41
20. Wu Q, Zheng Y Chen D et al: Aberrant expression of decoy receptor 3 in human breast cancer: relevance to lymphangiogensis. J Surq Res, 2014; 188: 459–65
21. Connolly K, Cho YH, Duan R et al: In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor. J Pharmacol Exp Ther, 2001; 298: 25–33
22. Pitti RM, Marsters SA, Lawrence DA et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 1998; 396: 699–703
23. Migone TS, Zhang J, Luo X et al: TL1A is a TNF-like ligand for DR3 and TR6/ DcR3 and functions as a T cell contimulator. Immunity, 2002; 16: 479–92
24. Hsu TL, Wu YY, Chang YC et al: Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol, 2005; 175: 5135–45
25. Zhang J, Salcedo TW, Wan X et al: Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest, 2001; 107: 1359–468
26. Hsu MJ, Lin WW, Taso WC et al: Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res, 2004; 292: 241–51
27. Kim S, Fotiadu A, Kotoula V: Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol, 2005; 115: 286–94
28. Chang YC, Hsu TL, Lin HH et al: Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol, 2004; 75: 486–94
29. Shi G, Wu Y, Zhang J, Wu J: Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol, 2003; 171: 3407–14
30. Hsu TL, Chang YC, Chen SJ et al: Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol, 2002; 168: 4846–53
31. You RI, Chang YC, Chen PM et al: Apoptosis dendritic cells induced by decoy receptor 3 (DcR3). Blood, 2008; 111: 1480–88
32. Yang MSZ, Chen G, Dang YW, Luo DZ: Effect of DcR3 on apoptosis of breast carcinoma cells and expression in sera of breast carcinoma patients. Cancer Research on Prevention and Treatment, 2011; 7: 784–7+798
33. Ge ZC, Sanders AJ, Ye L et al: Expression of death decoy receptor-3(DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro. J Exp Ther and Oncol, 2011; 9(2): 109–18
34. Wang FJ, Wang KK, Chen XB et al: Correlation between DcR3 expression and T cell subgroup in peripheral blood of uterine cervical cancer. J Immunol, 2015; 3: 246–49
35. Lin JX, Peng Y, Yu GF et al: Effect of DcR3 interference on the proliferation of ovarian cancer cell CAOV3. J Pra Med, 2015; 16: 2601–4
36. Connor JP, Felder M: Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor (DcR3) and is association with platinum resistance. Gynecol Oncol, 2008; 111: 330–35
37. Peyre CG, Hagen JA, DeMeester ER et al: The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg, 2008; 248: 549–56
38. Wilson M, Rosato EL, Chojnacki KA et al: Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res, 2008; 146: 11–15
39. Torres CM, Wang HH, Turner JR et al: Pathologic prognostic factors in esophageal squamous cell carcinoma: a follow-up study of 74 patients with or without preoperative chemoradiation therapy. Mod Pathol, 1999; 12: 961–68
40. Schoppmann SF, Jesch B, Zacherl J et al: Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery, 2013; 153: 526–34
41. Davies AR, Pillai A, Sinha P et al: Factors associated with early recurrence and death after esophagectomy for cancer. J Surg Oncol, 2014; 109: 459–64
42. Huang SN, Chen G, Dang YW, Chen LH: Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. Scientific World J, 2014; 10: 1155–62
43. Ruan Y, Huang S, He D et al: Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells. Neoplasma, 2015; 62(4): 574–81